Innovation in the pharmaceutical industry: New estimates of R&D costs.
By J. DiMasi, Henry G. Grabowski, R. Hansen. 2016
1,418 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Immunology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
In Immunology
Citations in the corpus
- Opportunities and obstacles for deep learning in biology and medicine (2017, background): “Drug repositioning (or repurposing) is an attractive option for delivering new drugs to the market because of the high costs and failure rates associated with more traditional drug discovery approaches [278,279].”
- Artificial intelligence to deep learning: machine intelligence approach for drug discovery (2021, background): “It usually takes 12 years to bring a new drug to the market, which can cost up to 3 billion USD [445].”
- TorchDrug: A Powerful and Flexible Machine Learning Platform for Drug Discovery (2022, background): “Drug discovery is a long and costly process, taking on average 10 years and costing 2.5 billion US dollars to develop a new drug (DiMasi et al., 2016).”
- The next generation of evidence-based medicine (2023, neutral): “3, 4).”
- MolGenSurvey: A Systematic Survey in Machine Learning Models for Molecule Design (2022, methodology): “Traditional methods, e.g., high-throughput screening (HTS) technologies, search over existing molecule databases but rely heavily on enumeration, thus are very time-consuming and laborious [2], [3].”
- Evaluating drug targets through human loss-of-function genetic variation (2019, positive): “With the cost of drug discovery driven overwhelmingly by failure 50 , successful interpretation of LoF data to select the right targets and right clinical pathways will yield outsize benefits for research productivity and, ultimately, human health.”